Videos

Dr. Peter Voorhees discusses the evolving treatment landscape for smoldering multiple myeloma, highlighting new therapies and clinical trial opportunities.

Dr. Peter Voorhees discusses risk stratification in smoldering multiple myeloma, highlighting the IMWG criteria and the benefits of daratumumab treatment.

Peter Voorhees, MD, discusses groundbreaking AQUILA study results, highlighting daratumumab's significant impact on high-risk smoldering multiple myeloma treatment.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.

Che-Kai Tsao, MD, MS, discusses new approaches that could change the standard of care for metastatic hormone-sensitive prostate cancer.

Peter Voorhees, MD, discusses the AQUILA study's impact on treating patients with high-risk smoldering multiple myeloma, paving the way for new therapies.

This discussion looks ahead at how the role of PD-1 inhibitors may continue to evolve in the treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (GEJ) cancers.

This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the management of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (GEJ) cancers.

This discussion highlights several emerging therapeutic approaches that are shaping future directions in advanced gastric and gastroesophageal junction (GEJ) cancers.

This discussion outlines several emerging therapeutic approaches currently under investigation for advanced gastric and gastroesophageal junction (GEJ) cancers.

This discussion reviews the dosing flexibility available for PD-1 inhibitors used in advanced gastric and gastroesophageal junction (GEJ) cancers.

This discussion reviews the dosing flexibility available for PD-1 inhibitors used in advanced gastric and gastroesophageal junction (GEJ) cancers.

This discussion reviews the key safety considerations for checkpoint inhibitors used in advanced esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (GEJ) cancers.

This discussion reviews key safety considerations for immune checkpoint inhibitors used in advanced esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (GEJ) cancers.

This discussion reviews the ongoing HERIZON-GEA-01 trial, a global, randomized Phase 3 study evaluating zanidatamab as a potential first-line treatment for HER2-positive gastric and gastroesophageal junction (GEJ) adenocarcinoma.

This discussion reviews the ongoing HERIZON-GEA-01 trial, a global Phase 3 study evaluating zanidatamab as part of first-line therapy for HER2-positive gastric and gastroesophageal junction (GEJ) adenocarcinoma.

This discussion summarizes the KEYNOTE-811 trial, which evaluated the addition of pembrolizumab to trastuzumab and platinum-based chemotherapy for patients with previously untreated, HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.

This discussion reviews the KEYNOTE-811 trial, which evaluates the addition of pembrolizumab to trastuzumab and chemotherapy in the first-line treatment of HER2-positive gastric and gastroesophageal junction (GEJ) adenocarcinoma.

This discussion provides a focused overview of the RATIONALE-305 trial, which evaluated tislelizumab in combination with platinum-based chemotherapy as first-line treatment for patients with previously untreated, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Emerging MRD tests show promise in enhancing breast cancer treatment by improving risk stratification and clinical outcomes for patients.

Expert explores innovative strategies for managing early stage breast cancer, focusing on minimal residual disease and potential treatment adjustments.

Early-stage breast cancer patients face challenges with ctDNA detection, highlighting the need for clinical trials to improve outcomes and reduce recurrence risks.

Explore the advancements in minimal residual disease (MRD) assays, comparing tumor-informed and tumor-agnostic methods for enhanced cancer detection and treatment strategies.

Panelists reflect on clinical experience with immunotherapy combinations, the role of biomarkers, and the future of personalized melanoma treatment.

Andrew M. Brunner, MD, discusses challenges and progress in identifying treatment for patients with transfusion-dependent myelodysplastic syndromes.

Dr. Christian S. Hinrichs discusses the future of specialized cell therapies, predicting broader access for community clinics similar to CAR T cell treatments.

Dr. Hinrichs emphasizes the critical need for early referrals and screenings for patients considering advanced cell therapies, enhancing treatment outcomes.

Panelists discuss real-world data comparing outcomes of different immunotherapy combinations for advanced melanoma.